Pancreatic ductal adenocarcinoma, the most prevalent form of pancreatic cancer, is currently the fourth leading cause of death in the United States. It is projected to become the second leading cause of death within the next decade due to its poor prognosis and rising incidence. FOLFIRINOX or gemcitabine plus nab-paclitaxel are recommended as the first-line treatments for this aggressive cancer.
The company we are profiling today is Lisata Therapeutics Inc. (LSTA), which is developing a drug for patients with metastatic pancreatic ductal adenocarcinoma.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.